- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/50 - Fibroblast growth factor [FGF]
Patent holdings for IPC class C07K 14/50
Total number of patents in this class: 725
10-year publication summary
|
75
|
71
|
68
|
51
|
53
|
48
|
59
|
58
|
63
|
20
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| NGM Biopharmaceuticals, Inc. | 179 |
41 |
| Amgen Inc. | 4072 |
24 |
| Novartis AG | 10847 |
21 |
| Florida State University Research Foundation, Inc. | 743 |
20 |
| New York University | 1745 |
20 |
| The Salk Institute for Biological Studies | 445 |
18 |
| Bristol-myers Squibb Company | 4878 |
15 |
| The Regents of the University of California | 19898 |
14 |
| Yuhan Corporation | 225 |
13 |
| Novo Nordisk A/S | 2288 |
12 |
| Sanofi | 4041 |
11 |
| Wisconsin Alumni Research Foundation | 3877 |
10 |
| Ambrx, Inc. | 181 |
10 |
| Eli Lilly and Company | 3841 |
10 |
| Sunshine Lake Pharma Co., Ltd. | 599 |
9 |
| 89bio Ltd | 19 |
9 |
| 89bio, Inc. | 15 |
8 |
| Ubiprotein, Corp. | 12 |
8 |
| Board of Trustees of the University of Arkansas | 811 |
7 |
| Trefoil Therapeutics, Inc. | 12 |
7 |
| Other owners | 438 |